# Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

> **NCT02680002** · PHASE2 · COMPLETED · sponsor: **Biomedical Advanced Research and Development Authority** · enrollment: 422 (actual)

## Conditions studied

- A/Vietnam/H5N1 Influenza Virus

## Interventions

- **BIOLOGICAL:** 7.5 mcg H5N1 (stored as monobulk)
- **BIOLOGICAL:** 15 mcg H5N1 (stored as monobulk)
- **BIOLOGICAL:** 90 mcg H5N1 (stored as monobulk)
- **BIOLOGICAL:** 90 mcg H5N1 (stored in vials)
- **OTHER:** MF59
- **OTHER:** MF59 (stored as monobulk)

## Key facts

- **NCT ID:** NCT02680002
- **Lead sponsor:** Biomedical Advanced Research and Development Authority
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2016-05-13
- **Final completion:** 2017-03-31
- **Target enrollment:** 422 (ACTUAL)
- **Last updated:** 2020-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02680002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02680002, "Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02680002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*